From biomedicinal to in silico models and back to therapeutics : a review on the advancement of peptidic modeling
Bioactive peptides participate in numerous metabolic functions of living organisms and have emerged as potential therapeutics on a diverse range of diseases. Albeit peptide design does not go without challenges, overwhelming advancements on in silico methodologies have increased the scope of peptide-based drug design and discovery to an unprecedented amount. Within an in silico model versus an experimental validation scenario, this review aims to summarize and discuss how different in silico techniques contribute at present to the design of peptide-based molecules. Published in silico results from 2014 to 2018 were selected and discriminated in major methodological groups, allowing a transversal analysis, promoting a landscape vision and asserting its increasing value in drug design.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Future medicinal chemistry - 11(2019), 17 vom: 15. Sept., Seite 2313-2331 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Moura, Ana S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Docking |
|---|
| Anmerkungen: |
Date Completed 30.06.2020 Date Revised 30.06.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.4155/fmc-2018-0365 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM301891680 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM301891680 | ||
| 003 | DE-627 | ||
| 005 | 20231225105552.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/fmc-2018-0365 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1006.xml |
| 035 | |a (DE-627)NLM301891680 | ||
| 035 | |a (NLM)31581914 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Moura, Ana S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a From biomedicinal to in silico models and back to therapeutics |b a review on the advancement of peptidic modeling |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.06.2020 | ||
| 500 | |a Date Revised 30.06.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Bioactive peptides participate in numerous metabolic functions of living organisms and have emerged as potential therapeutics on a diverse range of diseases. Albeit peptide design does not go without challenges, overwhelming advancements on in silico methodologies have increased the scope of peptide-based drug design and discovery to an unprecedented amount. Within an in silico model versus an experimental validation scenario, this review aims to summarize and discuss how different in silico techniques contribute at present to the design of peptide-based molecules. Published in silico results from 2014 to 2018 were selected and discriminated in major methodological groups, allowing a transversal analysis, promoting a landscape vision and asserting its increasing value in drug design | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a QSAR | |
| 650 | 4 | |a docking | |
| 650 | 4 | |a homology model | |
| 650 | 4 | |a molecular dynamics | |
| 650 | 4 | |a peptide design | |
| 650 | 4 | |a pharmacophore mapping | |
| 650 | 7 | |a Ligands |2 NLM | |
| 650 | 7 | |a Peptides |2 NLM | |
| 700 | 1 | |a Halder, Amit K |e verfasserin |4 aut | |
| 700 | 1 | |a Ds Cordeiro, M Natália |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future medicinal chemistry |d 2009 |g 11(2019), 17 vom: 15. Sept., Seite 2313-2331 |w (DE-627)NLM194822109 |x 1756-8927 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2019 |g number:17 |g day:15 |g month:09 |g pages:2313-2331 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/fmc-2018-0365 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2019 |e 17 |b 15 |c 09 |h 2313-2331 | ||